MIF在非酒精性脂肪性肝病中的研究进展

Research Progress of MIF in Nonalcoholic Fatty Liver Disease

随着代谢性疾病患病率逐渐的增加,非酒精性脂肪性肝病(NAFLD)正在成为肝脏相关疾病和死亡的主要原因,目前NAFLD全球患病率约为30%,但目前还没有FDA批准用于治疗NAFLD的药物。NAFLD疾病的谱系从肝脏脂肪变性延伸到非酒精性脂肪性肝炎(NASH)。据统计大约20%的NAFLD患者可进展为NASH,从而进一步发展为肝纤维化、肝硬化或肝细胞癌(HCC)。继发于NASH的肝硬化已成为肝移植的第二大适应症,其患病率预计将逐年上升,并在未来超过所有其他移植适应症。因此,NAFLD已成为一个全球性的健康问题,造成了重大的社会经济负担。巨噬细胞迁移抑制因子(MIF)是一种多效性细胞因子,通过巨噬细胞对炎症的反应,抑制巨噬细胞的迁移,促进细胞因子的积累、增殖、活化和分泌,从而在炎症、自身免疫性疾病和肿瘤等疾病的发病机制中发挥关键作用。在过去的30年中,即使在肝病管理取得重大进展之后,全世界仍有数百万人患有急性或慢性肝病。越来越多的研究发现MIF在代谢相关性肝病中起着非常重要的作用。因此,本文旨在全面综述MIF作为多效性细胞因子在NAFLD中的作用、分子机制及临床证据,以期为今后的相关研究提供参考。

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease world-wide, affecting 30% of the world’s population. Cirrhosis secondary to nonalcoholic steatohepatitis (NASH) has become the second leading indication for liver transplantation, and its prevalence is expected to increase annually and surpass all other transplant indications in the future. As a result, NAFLD has become a global health problem with a significant socioeconomic burden. Macrophage migrate on inhibitory factor (MIF) is a pleiotropic cytokine that plays a key role in the pathogenesis of diseases such as inflammation, autoimmune diseases, and tumors by inhibiting macrophage mi-gration and promoting cytokine accumulation, proliferation, activation, and secretion through macrophage response to inflammation. Over the past 30 years, millions of people around the world have suffered from acute or chronic liver disease, even after significant advances in liver disease management.